At present, around 59 million adults worldwide have diabetes, about 64 million are diagnosed with heart failure, and ...

Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type ...

CHRISTMAS… it’s THE ultimate eating challenge. But for the millions of us reportedly on weight loss jabs, what misery awaits?

I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.

The Indian judiciary did well not to let Novo Nordisk extend its exclusive right to sell semaglutide, marketed as Ozempic and ...

A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of ...

Scientists have discovered that semaglutide, the active ingredient in drugs like Ozempic and Wegovy, offers a new benefit for ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

Amy Schumer's jaw-dropping divorce reveal has fans shook! Find out how the comedian dropped the bombshell in a way that only ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...